Tags

Type your tag names separated by a space and hit enter

Acceptability of hypothetical dengue vaccines among travelers.
J Travel Med. 2013 Nov-Dec; 20(6):346-51.JT

Abstract

BACKGROUND

Dengue viruses have spread widely in recent decades and cause tens of millions of infections mostly in tropical and subtropical areas. Vaccine candidates are being studied aggressively and may be ready for licensure soon.

METHODS

We surveyed patients with past or upcoming travel to dengue-endemic countries to assess rates and determinants of acceptance for four hypothetical dengue vaccines with variable efficacy and adverse event (AE) profiles. Acceptance ratios were calculated for vaccines with varied efficacy and AE risk.

RESULTS

Acceptance of the four hypothetical vaccines ranged from 54% for the vaccine with lower efficacy and serious AE risk to 95% for the vaccine with higher efficacy and minor AE risk. Given equal efficacy, vaccines with lower AE risk were better accepted than those with higher AE risk; given equivalent AE risk, vaccines with higher efficacy were better accepted than those with lower efficacy. History of Japanese encephalitis vaccination was associated with lower vaccine acceptance for one of the hypothetical vaccines. US-born travelers were more likely than non-US born travelers to accept a vaccine with 75% efficacy and a risk of minor AEs (p = 0.003). Compared with North American-born travelers, Asian- and African-born travelers were less likely to accept both vaccines with 75% efficacy.

CONCLUSIONS

Most travelers would accept a safe and efficacious dengue vaccine if one were available. Travelers valued fewer potential AEs over increased vaccine efficacy.

Authors+Show Affiliations

Maxwell Finland Laboratory for Infectious Diseases, Boston Medical Center, Boston, MA, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

24165380

Citation

Benoit, Christine M., et al. "Acceptability of Hypothetical Dengue Vaccines Among Travelers." Journal of Travel Medicine, vol. 20, no. 6, 2013, pp. 346-51.
Benoit CM, MacLeod WB, Hamer DH, et al. Acceptability of hypothetical dengue vaccines among travelers. J Travel Med. 2013;20(6):346-51.
Benoit, C. M., MacLeod, W. B., Hamer, D. H., Sanchez-Vegas, C., Chen, L. H., Wilson, M. E., Karchmer, A. W., Yanni, E., Hochberg, N. S., Ooi, W. W., Kogelman, L., & Barnett, E. D. (2013). Acceptability of hypothetical dengue vaccines among travelers. Journal of Travel Medicine, 20(6), 346-51. https://doi.org/10.1111/jtm.12056
Benoit CM, et al. Acceptability of Hypothetical Dengue Vaccines Among Travelers. J Travel Med. 2013 Nov-Dec;20(6):346-51. PubMed PMID: 24165380.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Acceptability of hypothetical dengue vaccines among travelers. AU - Benoit,Christine M, AU - MacLeod,William B, AU - Hamer,Davidson H, AU - Sanchez-Vegas,Carolina, AU - Chen,Lin H, AU - Wilson,Mary E, AU - Karchmer,Adolf W, AU - Yanni,Emad, AU - Hochberg,Natasha S, AU - Ooi,Winnie W, AU - Kogelman,Laura, AU - Barnett,Elizabeth D, Y1 - 2013/08/16/ PY - 2013/03/06/received PY - 2013/04/19/revised PY - 2013/05/17/accepted PY - 2013/10/30/entrez PY - 2013/10/30/pubmed PY - 2014/7/16/medline SP - 346 EP - 51 JF - Journal of travel medicine JO - J Travel Med VL - 20 IS - 6 N2 - BACKGROUND: Dengue viruses have spread widely in recent decades and cause tens of millions of infections mostly in tropical and subtropical areas. Vaccine candidates are being studied aggressively and may be ready for licensure soon. METHODS: We surveyed patients with past or upcoming travel to dengue-endemic countries to assess rates and determinants of acceptance for four hypothetical dengue vaccines with variable efficacy and adverse event (AE) profiles. Acceptance ratios were calculated for vaccines with varied efficacy and AE risk. RESULTS: Acceptance of the four hypothetical vaccines ranged from 54% for the vaccine with lower efficacy and serious AE risk to 95% for the vaccine with higher efficacy and minor AE risk. Given equal efficacy, vaccines with lower AE risk were better accepted than those with higher AE risk; given equivalent AE risk, vaccines with higher efficacy were better accepted than those with lower efficacy. History of Japanese encephalitis vaccination was associated with lower vaccine acceptance for one of the hypothetical vaccines. US-born travelers were more likely than non-US born travelers to accept a vaccine with 75% efficacy and a risk of minor AEs (p = 0.003). Compared with North American-born travelers, Asian- and African-born travelers were less likely to accept both vaccines with 75% efficacy. CONCLUSIONS: Most travelers would accept a safe and efficacious dengue vaccine if one were available. Travelers valued fewer potential AEs over increased vaccine efficacy. SN - 1708-8305 UR - https://www.unboundmedicine.com/medline/citation/24165380/Acceptability_of_hypothetical_dengue_vaccines_among_travelers_ L2 - https://academic.oup.com/jtm/article-lookup/doi/10.1111/jtm.12056 DB - PRIME DP - Unbound Medicine ER -